MCID: SVR005
MIFTS: 48

Severe Pre-Eclampsia

Categories: Cardiovascular diseases, Rare diseases

Aliases & Classifications for Severe Pre-Eclampsia

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 52 14 69
Severe Pre-Eclampsia, Antepartum Condition or Complication 69
Severe Pre-Eclampsia, Postpartum Condition or Complication 69
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Preeclampsia 12
Severe Toxemia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 35 642.50
ICD10 33 O14.1
UMLS 69 C0156669

Summaries for Severe Pre-Eclampsia

Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following

MalaCards based summary : Severe Pre-Eclampsia, also known as severe pre-eclampsia, antepartum condition or complication, is related to preeclampsia/eclampsia 1 and hellp syndrome. An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Fluid shear stress and atherosclerosis. The drugs Methyldopa and Remifentanil have been mentioned in the context of this disorder. Affiliated tissues include placenta, testes and colon, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Severe Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
id Related Disease Score Top Affiliating Genes
1 preeclampsia/eclampsia 1 27.0 APOH F5 HLA-G LEP LGALS13 PGF
2 hellp syndrome 11.4
3 pre-eclampsia 11.0
4 eclampsia 11.0
5 kidney pelvis papillary carcinoma 10.7 MMP9 VEGFA
6 diamond-blackfan anemia 10.7 LEP MMP9
7 acquired hypoprothrombinemia 10.6 ADIPOQ LEP
8 male reproductive organ cancer 10.6 MMP9 VEGFA
9 hepatic vascular disease 10.6 LEP MMP9 VEGFA
10 retinitis pigmentosa 70 10.6 ALB VEGFA
11 leigh syndrome with leukodystrophy 10.5 ADIPOQ LEP
12 neuropathy, hereditary sensory and autonomic, type vi 10.5 MMP9 VCAM1 VEGFA
13 lipoic acid biosynthesis defects 10.5 LEP LEPR
14 submucous uterine fibroid 10.5 ALB VEGFA
15 calciphylaxis 10.5 ALB MMP9 VEGFA
16 gallbladder cancer 10.4 ALB MMP9 VEGFA
17 scleredema adultorum 10.4 ADIPOQ LEP VCAM1
18 corpus callosum agenesis of blepharophimosis robin type 10.4 ADIPOQ LEP VCAM1
19 chronic myelomonocytic leukemia 10.4 ALB LEP VCAM1
20 hyperlipoproteinemia type iv 10.3 ADIPOQ ALB LEP
21 idiopathic progressive polyneuropathy 10.3 LEP PGF VCAM1
22 fragile x syndrome type 2 10.3 ALB SERPINC1
23 hypertrichosis 10.3 ADIPOQ ALB LEP
24 diabetic encephalopathy 10.2 ADIPOQ LEP LEPR
25 inherited metabolic disorder 10.2 ADIPOQ LEP LEPR
26 short bowel syndrome 10.2 ADIPOQ LEP LEPR
27 chromosome 11p13 deletion syndrome, distal 10.2 ADIPOQ LEP LEPR
28 nasal cavity adenocarcinoma 10.2 ALB MMP9
29 cataract 10.1 ALB SERPINC1
30 congenital ichthyosiform erythroderma 10.1 PGF VEGFA
31 myelophthisic anemia 10.1 ADIPOQ MMP9 VCAM1
32 acitretin/etretinate embryopathy 10.1 PGF VEGFA
33 amelogenesis imperfecta hypomaturation type 10.1 F5 MMP9
34 dientamoebiasis 10.1 ADIPOQ LEP LEPR
35 hidradenoma 10.1 FGR LEP PGF VEGFA
36 citrullinemia, adult-onset type ii 10.1 ALB PGF VCAM1 VEGFA
37 retinitis 10.1
38 periampullary adenoma 10.1 ADIPOQ LEP LEPR VEGFA
39 peroneal neuropathy 10.0 ADIPOQ ALB LEP
40 perinatal necrotizing enterocolitis 10.0 ADIPOQ ALB LEP LEPR
41 mucolipidoses 10.0 ADIPOQ ALB LEP LEPR
42 cerebritis 10.0
43 hemolytic anemia 10.0
44 retinal detachment 10.0
45 endotheliitis 10.0
46 survival motor neuron spinal muscular atrophy 10.0 ADIPOQ ALB LEP LEPR
47 ovarian hyperstimulation syndrome 10.0 ALB F5 VEGFA
48 mcgillivray syndrome 10.0 APOH F5
49 angina pectoris 10.0 ALB SERPINC1 VCAM1 VEGFA
50 accessory deep peroneal nerve 9.9 APOH F5

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia

Symptoms & Phenotypes for Severe Pre-Eclampsia

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.3 LEPR MMP9 PGF SERPINC1 VCAM1 VEGFA
2 homeostasis/metabolism MP:0005376 10.3 ADIPOQ ALB APLN APOH F5 HIF1AN
3 growth/size/body region MP:0005378 10.19 ADIPOQ APLN F5 HIF1AN LEP LEPR
4 hematopoietic system MP:0005397 10.13 ADIPOQ FGR HLA-G LEP LEPR MMP9
5 immune system MP:0005387 10.13 ADIPOQ FGR HLA-G LEP LEPR MMP9
6 embryo MP:0005380 10.11 APLN F5 LEP LEPR PGF SERPINC1
7 liver/biliary system MP:0005370 9.97 ADIPOQ ALB F5 HIF1AN LEP LEPR
8 integument MP:0010771 9.95 MMP9 ADIPOQ F5 LEP LEPR PGF
9 muscle MP:0005369 9.92 ALB APLN HIF1AN LEP LEPR MMP9
10 neoplasm MP:0002006 9.8 ADIPOQ ALB LEP LEPR MMP9 PGF
11 renal/urinary system MP:0005367 9.7 ADIPOQ ALB LEP LEPR MMP9 SERPINC1
12 respiratory system MP:0005388 9.5 ADIPOQ HIF1AN LEP LEPR MMP9 PGF
13 vision/eye MP:0005391 9.17 LEP LEPR MMP9 PGF SERPINC1 VEGFA

Drugs & Therapeutics for Severe Pre-Eclampsia

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4 555-30-6 38853
2
Remifentanil Approved Phase 4,Phase 2 132875-61-7 60815
3
Labetalol Approved Phase 4,Phase 2,Phase 3 36894-69-6 3869
4
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 2,Phase 3 7487-88-9 24083
5
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
6
Captopril Approved Phase 4 62571-86-2 44093
7
Clonidine Approved Phase 4 4205-90-7 2803
8
Dalteparin Approved Phase 4,Phase 3 9005-49-6
9
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
11
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
12
Ibuprofen Approved Phase 4,Phase 2,Phase 3 15687-27-1 3672
13
Nifedipine Approved Phase 4,Phase 3 21829-25-4 4485
14
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
15
Thrombin Approved Phase 4
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 143 6006
18 tannic acid Approved, Nutraceutical Phase 4,Phase 3
19 Antihypertensive Agents Phase 4,Phase 3,Phase 2
20 Analgesics Phase 4,Phase 2,Phase 3
21 Analgesics, Opioid Phase 4,Phase 2
22 Anesthetics Phase 4,Phase 2,Phase 3
23 Anesthetics, General Phase 4,Phase 2
24 Anesthetics, Intravenous Phase 4,Phase 2
25 Central Nervous System Depressants Phase 4,Phase 2,Phase 3
26 Hypnotics and Sedatives Phase 4,Phase 2
27 Narcotics Phase 4,Phase 2
28 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
29 calcium channel blockers Phase 4,Phase 3,Phase 2
30 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
31 Adrenergic Agents Phase 4,Phase 3,Phase 2
32 Autonomic Agents Phase 4,Phase 2,Phase 3
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
34 Antibodies Phase 4,Phase 2
35 Antibodies, Antiphospholipid Phase 4
36 Anticoagulants Phase 4,Phase 3,Phase 2
37 Immunoglobulins Phase 4,Phase 2
38 Micronutrients Phase 4,Phase 3
39 Trace Elements Phase 4,Phase 3
40 Vitamins Phase 4,Phase 3
41 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2
42 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
43 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
44 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 3
45 Vasodilator Agents Phase 4,Phase 3,Phase 2
46 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3
47 Anticonvulsants Phase 4,Phase 2,Phase 3
48 Pharmaceutical Solutions Phase 4,Phase 3
49 Tocolytic Agents Phase 4,Phase 2,Phase 3
50 diuretics Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 105)

id Name Status NCT ID Phase Drugs
1 Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape) Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Remifentanil for General Anesthesia in Preeclamptics Unknown status NCT00567957 Phase 4 Remifentanil;Saline
3 Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
4 A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
5 Diuretics for Postpartum High Blood Pressure in Preeclampsia Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
6 Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
7 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
8 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
9 Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Recruiting NCT03164304 Phase 4 Magnesium Sulfate
10 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Recruiting NCT02911701 Phase 4 Acetaminophen;Ibuprofen
11 Early Vascular Adjustments During Hypertensive Pregnancy Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
12 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Recruiting NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
13 The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Recruiting NCT02891174 Phase 4 Ibuprofen;Acetaminophen
14 LMWH to Prevent Preeclampsia and Fetal Growth Restriction Terminated NCT00260520 Phase 4 Dalteparin
15 Different Schemes of Magnesium Sulfate for Preeclampsia Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
16 Atenativ Effect on Uterine Blood Flow and Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
17 Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia Unknown status NCT01382732 Phase 3 Carbetocin;Oxytocin
18 Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine Unknown status NCT00409253 Phase 3 URAPIDIL (EUPRESSYL*);NICARDIPINE
19 Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients. Unknown status NCT02050529 Phase 2, Phase 3 Labetalol;Hydralazine
20 Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol Completed NCT02086994 Phase 3 misoprostol;carbetocin
21 Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Completed NCT02307201 Phase 2, Phase 3 Magnesium Sulfate
22 Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
23 Magnesium Sulfate in Pregnancy and Postpartum Completed NCT02317146 Phase 2, Phase 3 Magnesium Sulfate
24 Nonsteroidal Antiinflammatory Drugs in Women With Postpartum Pre-eclampsia Completed NCT01988298 Phase 2, Phase 3 Ibuprofen;Acetaminophen
25 New Magnesium Sulphate Protocol for Pre-eclampsia Completed NCT01846156 Phase 3 MgSO4
26 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
27 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) Completed NCT00135707 Phase 3
28 The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine Recruiting NCT02558023 Phase 3 Urapidil;Nicardipine
29 Magnesium Sulphate for Preterm Birth (MASP Study) Recruiting NCT01492608 Phase 3 Magnesium sulphate
30 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia Recruiting NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
31 Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia Recruiting NCT02989025 Phase 3 17 OHPC
32 A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders Recruiting NCT02336243 Phase 3
33 Evaluation of the Efficacy of Citrulline Supplementation on the Delay of Delivery for Women Hospitalized for Pre-eclampsia (CITRUPE) Recruiting NCT02801695 Phase 2, Phase 3 Citrulline;Placebo
34 Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Not yet recruiting NCT03237819 Phase 3 Sulfate, Magnesium;Placebo - Concentrate
35 Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia Trial Not yet recruiting NCT02007837 Phase 3 Combined aspirin and multinutrient supplement
36 Esomeprazole in Treatment of Early Onset Preeclampsia (ESOPE Trial) Not yet recruiting NCT03213639 Phase 2, Phase 3 Esomeprazole 40 mg Oral Tablet;Placebo Oral Tablet
37 L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR) Terminated NCT00549575 Phase 3 L ARG;Placebo
38 Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean Withdrawn NCT01451060 Phase 3 Metaraminol;Ephedrine
39 Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
40 Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery Withdrawn NCT01796522 Phase 3 progesterone 200 mg / day vaginally;nifedipine (60 mg / day orally)
41 Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
42 Efficacy Study of Digibind for Treatment of Severe Preeclampsia Completed NCT00158743 Phase 2 Anti-digoxin antibody (FAB fragment)
43 Dexmedetomidine vs. Remifentanil for Pre-eclampsia During Caesarean Delivery Completed NCT01766089 Phase 2 Remifentanil;Dexmedetomidine
44 Disease Modification in Toxaemia of Pregnancy Completed NCT00175695 Phase 2 Recombinant human activated protein C or drotrecogin alpha
45 Safety and Acceptability of a Vaginal Microbicide Completed NCT00111943 Phase 2 1% tenofovir gel
46 Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation Completed NCT01616615 Phase 2 Aspirin;placebo
47 Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects With Severe Preeclampsia Recruiting NCT03008616 Phase 2
48 Should Colon or Non-colon Originated Lesions be Distinguished? Recruiting NCT02939508 Phase 1, Phase 2
49 Prevention of Severe Postpartum Hypertension Recruiting NCT02450773 Phase 2 Furosemide;Potassium chloride;Placebo #1;Placebo #2
50 Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia Terminated NCT02286284 Phase 2

Search NIH Clinical Center for Severe Pre-Eclampsia

Genetic Tests for Severe Pre-Eclampsia

Anatomical Context for Severe Pre-Eclampsia

MalaCards organs/tissues related to Severe Pre-Eclampsia:

39
Placenta, Testes, Colon, Liver, Endothelial, Bone, Kidney

Publications for Severe Pre-Eclampsia

Articles related to Severe Pre-Eclampsia:

(show top 50) (show all 319)
id Title Authors Year
1
Re: Lung and cardiac ultrasound for hemodynamic monitoring of patients with severe pre-eclampsia. J. Ambrozic, G. Brzan Simenc, K. Prokselj, N. Tulz, M. Cvijic and M. Lucovnik. Ultrasound Obstet Gynecol 2017; 49: 104-109. ( 28058788 )
2017
2
Evaluation of Placental mir-155-5p and Long Non-coding RNA sONE Expression in Patients with Severe Pre-eclampsia. ( 28868266 )
2017
3
Re: Serious maternal complications in relation to severe pre-eclampsia: a retrospective cohort study of the impact of hospital volume; Severe maternal morbidity requires regionalisation of obstetric critical care; Guilt, blame and litigation: can an overenthusiastic 'safety culture' cause harm?: Maternal mortality: the heavy psychological burden on centre obstetricians. ( 28670731 )
2017
4
Validation of fullPIERS model for prediction of adverse outcomes among women with severe pre-eclampsia. ( 28475234 )
2017
5
Severe pre-eclampsia before 26A weeks of gestation: how should we counsel women? ( 28229528 )
2017
6
Lung and cardiac ultrasound for hemodynamic monitoring of patients with severe pre-eclampsia. ( 27736042 )
2017
7
Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction. ( 28503744 )
2017
8
Assessment of quality of care among in-patients with postpartum haemorrhage and severe pre-eclampsia at st. Francis hospital nsambya: a criteria-based audit. ( 28086822 )
2017
9
Prediction of severe pre-eclampsia by a combination of sFlt-1, CT-pro ET1 and blood pressure: exploratory study. ( 28643875 )
2017
10
Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: A double-blind, randomized and placebo-controlled clinical study. ( 28726273 )
2017
11
Introduction of management protocol for early-onset severe pre-eclampsia. ( 28150368 )
2017
12
Severe pre-eclampsia is associated with alterations in cytotrophoblasts of the smooth chorion. ( 28232601 )
2017
13
Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia. ( 27461873 )
2016
14
Prospective assessment of neurodevelopment in children following a pregnancy complicated by severe pre-eclampsia. ( 27388354 )
2016
15
Relation between Helicobacter pylori infection and severe pre-eclampsia complicated by intrauterine growth restriction in a rural area in Egypt. ( 27624279 )
2016
16
Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. ( 26782635 )
2016
17
Maternal cardiac haemodynamics in severe pre-eclampsia complicated by acute pulmonary oedema: A review. ( 27866432 )
2016
18
Serious maternal complications in relation to severe pre-eclampsia: a retrospective cohort study of the impact of hospital volume. ( 27770512 )
2016
19
Ibuprofen versus acetaminophen as a post-partum analgesic for women with severe pre-eclampsia: randomized clinical study. ( 27384376 )
2016
20
Author's reply re: Microcirculation in women with severe pre-eclampsia and HELLP syndrome: a case control study. ( 27531337 )
2016
21
Soluble vascular cell adhesion molecule-1 and magnesium sulfate with nifedipine treatment in Indonesian women with severe pre-eclampsia. ( 28203390 )
2016
22
Cardiac arrest during emergency cesarean section for severe pre-eclampsia and peripartum cardiomyopathy. ( 26927264 )
2016
23
Maternal and neonatal outcomes in women with severe pre-eclampsia undergoing cesarean section: a 10-year retrospective study from a single tertiary care center: anesthetic point of view. ( 26952582 )
2016
24
Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( 27578562 )
2016
25
Antiretrovirals causing severe pre-eclampsia. ( 27939465 )
2016
26
Re: Microcirculation in women with severe pre-eclampsia and HELLP syndrome: a case control study: Effect of timing of extracorporeal membrane oxygenation during HELLP syndrome. ( 27531338 )
2016
27
Risk factors for cardiopulmonary dysfunction in early-onset severe pre-eclampsia. ( 27452610 )
2016
28
Ovarian reserve in women with a previous history of severe pre-eclampsia. ( 27604242 )
2016
29
Antenatal corticosteroid therapy for foetal maturation in women with eclampsia and severe pre-eclampsia in a rural hospital in Western Tanzania. ( 27543098 )
2016
30
First trimester placental retinol-binding protein 4 (RBP4) and pregnancy-associated placental protein A (PAPP-A) in the prediction of early-onset severe pre-eclampsia. ( 25633269 )
2015
31
Third-trimester uterine artery Doppler measurement and maternal postpartum outcome among patients with severe pre-eclampsia. ( 26117553 )
2015
32
Case of soluble fms-like tyrosine kinase 1 apheresis in severe pre-eclampsia developed at 15 weeks' gestation. ( 26094569 )
2015
33
Association between decreased plasma levels of soluble human leukocyte antigen-G and severe pre-eclampsia. ( 26352061 )
2015
34
Vascular endothelial growth factor (VEGF)-634G/C polymorphism was associated with severe pre-eclampsia and lower serum VEGF level. ( 26486233 )
2015
35
Criteria-based audit of quality of care to women with severe pre-eclampsia and eclampsia in a referral hospital in Accra, Ghana. ( 25923663 )
2015
36
Circulating chromosome 19 miRNA cluster microRNAs in pregnant women with severe pre-eclampsia. ( 26224638 )
2015
37
Characteristics and outcomes of patients with eclampsia and severe pre-eclampsia in a rural hospital in Western Tanzania: a retrospective medical record study. ( 26350344 )
2015
38
Transthoracic echocardiographic assessment of haemodynamics in severe pre-eclampsia and HIV in South Africa. ( 25891669 )
2015
39
Expression of markers of endoplasmic reticulum stress-induced apoptosis in the placenta of women with early and late onset severe pre-eclampsia. ( 25675914 )
2015
40
[40-OR]: A causal model of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia. ( 25787390 )
2015
41
Are Meteorological Conditions within the First Trimester of Pregnancy Associated with the Risk of Severe Pre-Eclampsia? ( 26053449 )
2015
42
Complications and maternal mortality from severe pre-eclampsia during the first 48hours in an intensive care unit in Morocco. ( 25638711 )
2015
43
Severe pre-eclampsia complicated by HELLP syndrome alterations in the structure of the umbilical cord (morphometric and immunohistochemical study). ( 26019650 )
2015
44
The characteristic of Indonesia's pre-eclampsia: From obstetric intensive care with ventilator until epidemiologic and its molecular biology profile of pulmonary edema in severe pre-eclampsia. ( 26104647 )
2014
45
Cardiac tamponade in pregnancy during the treatment of severe pre-eclampsia: report of a case. ( 24738125 )
2014
46
A novel protocol for postpartum magnesium sulphate in severe pre-eclampsia: a randomized controlled pilot trial. ( 25483417 )
2014
47
Coagulation profile in severe pre-eclampsia and eclampsia in ilorin, Nigeria: implications for anaesthetic management in operative obstetrics. ( 25236827 )
2014
48
Transthoracic echocardiography in women with treated severe pre-eclampsia. ( 24673113 )
2014
49
Association between an abnormal cerebroplacental ratio and the development of severe pre-eclampsia. ( 25474554 )
2014
50
Maternal outcomes of magnesium sulphate and diazepam use in women with severe pre-eclampsia and eclampsia in Ethiopia. ( 25035717 )
2014

Variations for Severe Pre-Eclampsia

Expression for Severe Pre-Eclampsia

Search GEO for disease gene expression data for Severe Pre-Eclampsia.

Pathways for Severe Pre-Eclampsia

GO Terms for Severe Pre-Eclampsia

Cellular components related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ADIPOQ ALB APLN APOH F5 FGR
2 extracellular space GO:0005615 9.36 ADIPOQ ALB APLN APOH F5 LEP
3 platelet alpha granule lumen GO:0031093 9.33 ALB F5 VEGFA

Biological processes related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.76 LEP LEPR PGF VEGFA
2 response to ethanol GO:0045471 9.74 ADIPOQ LEP VCAM1
3 glucose homeostasis GO:0042593 9.73 ADIPOQ LEP LEPR
4 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.58 VCAM1 VEGFA
5 macrophage differentiation GO:0030225 9.58 MMP9 VEGFA
6 platelet degranulation GO:0002576 9.56 ALB APOH F5 VEGFA
7 energy reserve metabolic process GO:0006112 9.55 LEP LEPR
8 leukocyte tethering or rolling GO:0050901 9.54 LEP VCAM1
9 negative regulation of gluconeogenesis GO:0045721 9.52 ADIPOQ LEPR
10 induction of positive chemotaxis GO:0050930 9.51 PGF VEGFA
11 lactation GO:0007595 9.5 APLN SERPINC1 VEGFA
12 sexual reproduction GO:0019953 9.49 LEP LEPR
13 leptin-mediated signaling pathway GO:0033210 9.48 LEP LEPR
14 regulation of bone remodeling GO:0046850 9.43 LEP LEPR
15 positive regulation of mast cell chemotaxis GO:0060754 9.4 PGF VEGFA
16 negative regulation of vasoconstriction GO:0045906 9.37 APLN LEP
17 response to nutrient GO:0007584 9.26 ADIPOQ LEP SERPINC1 VCAM1
18 bone growth GO:0098868 9.16 LEP LEPR
19 response to hypoxia GO:0001666 9.02 ADIPOQ LEP PGF VCAM1 VEGFA

Molecular functions related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.33 ADIPOQ APLN LEP
2 heparin binding GO:0008201 9.26 APOH PGF SERPINC1 VEGFA
3 vascular endothelial growth factor receptor binding GO:0005172 8.62 PGF VEGFA

Sources for Severe Pre-Eclampsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....